Literature DB >> 17306555

Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes.

Omar Mangoush1, Sanjay Purkayastha, Saleem Haj-Yahia, James Kinross, Martin Hayward, Fabio Bartolozzi, Ara Darzi, Thanos Athanasiou.   

Abstract

Heparinization of the blood contact surface in cardiopulmonary bypass circuits has been promoted as an important step in the development of open heart surgery. As it decreases the inflammatory response resulting from the extracorporeal circulation, it may have a positive effect on clinical outcomes. This meta-analysis was carried out to examine if heparin-bonded circuits (HBCs) reduce the need for blood products and improve overall clinical outcome. A systematic literature search was performed to identify randomized controlled trials reporting outcomes of HBCs compared with non-HBCs. Primary outcomes assessed were postoperative blood/blood-product transfusion and blood loss. Secondary outcomes included all-cause mortality, acute postoperative myocardial infarction, stroke, re-sternotomy for postoperative bleeding, wound infection, atrial fibrillation, duration of ventilation, intensive care unit (ICU) and hospital-length of stay (LOS). Random effects meta-analytical techniques were applied to identify differences in outcomes between the two groups. Quality of the included studies and heterogeneity were assessed. From an initial review of 762-published studies, 41-randomized trials fulfilled the inclusion criteria, leaving 3434-patients' data for analysis. HBCs significantly decreased the incidence of blood transfusion required (OR=0.8; 95% CI=0.6:0.9, P=0.004). It also significantly decreased re-sternotomy (OR=0.6; 95% CI=0.4:0.8, P=0.002), duration of ventilation (WMD= -1.3h; 95% CI= -1.9:-0.6, P<0.001), ICU-LOS (WMD= -9.3h; 95% CI=-14.7:-3.9, P<0.001) and hospital-LOS (WMD= -0.5 day; 95% CI= -0.9:-0.1, P=0.02). HBCs had no effect on other adverse events evaluated. Although HBCs showed a positive effect on some of the clinical outcomes, we identified only marginal differences for other outcomes. Further evaluation of the cost-effectiveness of this technology is required.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17306555     DOI: 10.1016/j.ejcts.2007.01.029

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  19 in total

Review 1.  The artificial endothelium.

Authors:  Melissa M Reynolds; Gail M Annich
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

Review 2.  [Cardiopulmonary bypass in cardiac surgery].

Authors:  T Baehner; O Boehm; C Probst; B Poetzsch; A Hoeft; G Baumgarten; P Knuefermann
Journal:  Anaesthesist       Date:  2012-10       Impact factor: 1.041

3.  Mimicking the Endothelium: Dual Action Heparinized Nitric Oxide Releasing Surface.

Authors:  Ryan Devine; Marcus J Goudie; Priyadarshini Singha; Chad Schmiedt; Megan Douglass; Elizabeth J Brisbois; Hitesh Handa
Journal:  ACS Appl Mater Interfaces       Date:  2020-04-22       Impact factor: 9.229

Review 4.  VV extracorporeal life support for the Third Millennium: will we need anticoagulation?

Authors:  Danny Eytan; Yuval Bitterman; Gail M Annich
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 5.  Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit?

Authors:  Sarah Mahmood; Haris Bilal; Mahvash Zaman; Augustine Tang
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-01-06

6.  Extracorporeal membrane oxygenation circuitry.

Authors:  Laurance Lequier; Stephen B Horton; D Michael McMullan; Robert H Bartlett
Journal:  Pediatr Crit Care Med       Date:  2013-06       Impact factor: 3.624

Review 7.  Anticoagulation strategies in extracorporeal circulatory devices in adult populations.

Authors:  Catherine Kato; Michael Oakes; Morris Kim; Anish Desai; Sven R Olson; Vikram Raghunathan; Joseph J Shatzel
Journal:  Eur J Haematol       Date:  2020-10-18       Impact factor: 2.997

8.  Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review.

Authors:  Sven R Olson; Catherine R Murphree; David Zonies; Andrew D Meyer; Owen J T Mccarty; Thomas G Deloughery; Joseph J Shatzel
Journal:  ASAIO J       Date:  2021-03-01       Impact factor: 3.826

Review 9.  Statin prophylaxis and inflammatory mediators following cardiopulmonary bypass: a systematic review.

Authors:  Catherine Morgan; Michael Zappitelli; Peter Gill
Journal:  Crit Care       Date:  2009-10-20       Impact factor: 9.097

Review 10.  Extracorporeal Membrane Oxygenation Use in Thoracic Surgery.

Authors:  Pavel Suk; Vladimír Šrámek; Ivan Čundrle
Journal:  Membranes (Basel)       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.